Telesis Bio, a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, announced that it has entered into a convertible preferred stock purchase agreement (the Purchase Agreement) to sell shares of a new series of convertible preferred stock in a private placement. The financing was led by Novalis LifeSciences and Northpond Ventures and is expected to result in gross proceeds to the Company of up to approximately $21 million.

Telesis Bio is empowering scientists to create novel, synthetic biology-enabled solutions for many of humanity's greatest challenges. With their revolutionary Gibson SOLA Enzymatic Synthesis platform, Telesis Bio is transforming the industry by providing non-toxic, high-fidelity, and scalable DNA synthesis. The Gibson SOLA platform, combined with award-winning BioXp® systems, enables rapid, accurate, and reproducible writing of DNA and mRNA, automating and optimizing the entire synthesis, cloning, and amplification workflow in customers' laboratories. Scientists worldwide leverage Telesis Bio's technology to accelerate the design-build-test paradigm, driving innovation in precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy.